This document focuses on updating procedures for monitoring and evaluation in line with the program’s first component: to interrupt transmission of LF through MDA. Available in
This article provides an insight of how the Tanzania Lymphatic Filariasis Programme began and discusses key areas in the programme’s design. Malecela et al, Annals
Abstract on the first 8 years of The Global Programme to Eliminate Lymphatic Filariasis. Hooper et al, Annals of Tropical Medicine & Parasitology, Volume 103, 2009 –
Abstract on progress made in preventing the disability of lymphatic filariasis, the monitoring and evaluation of such disability and its control, and the integration
Abstract addressing the central role that filariasis patients have played in the Tanzania Lymphatic Filariasis Elimination Programme to date, and covering some of the clinical
Abstract on the unique private-sector collaboration of the pharmaceutical companies GlaxoSmithKline (GSK) and Merck & Co., Inc., Kenilworth, N.J., U.S.A.,* to support the global efforts to
Abstract on the integration of mass drug administrations against multiple NTDs. Hopkins, Annals of Tropical Medicine & Parasitology, Volume 103, 2009 – Issue sup1.
Article on a symposium held to commemorate the 10th anniversary of the donation of Mectizan® and albendazole for the elimination of lymphatic filariasis. Hopkins
Abstract on the Mectizan® Donation Program (MDP), which was launched in 1987 by Merck & Co., Inc., Kenilworth, N.J., U.S.A.* Thylefors, Annals of Tropical Medicine and
WHO World Health Assembly Resolution on Lymphatic Filariasis. WHA 50.29, 1997 RESOLUTIONS AND DECISIONS1 WHA50.29 Elimination of lymphatic filariasis as a public health
